Sylwia Jancik
Overview
Explore the profile of Sylwia Jancik including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
435
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Slavkovsky R, Stranska J, Venskova V, Jancik S, Kotkova L, Simova J, et al.
Neoplasma
. 2021 Dec;
69(1):203-215.
PMID: 34881628
The presence of wild-type RAS alleles, as determined by genotyping codons 12, 13, 59, 61, 117, and 146, is a prerequisite for personalized anti-EGFR treatment of metastatic colorectal cancer (mCRC)...
2.
Felfoul O, Mohammadi M, Taherkhani S, de Lanauze D, Xu Y, Loghin D, et al.
Nat Nanotechnol
. 2016 Nov;
11(11):941-947.
PMID: 27525475
Oxygen-depleted hypoxic regions in the tumour are generally resistant to therapies. Although nanocarriers have been used to deliver drugs, the targeting ratios have been very low. Here, we show that...
3.
Stranska J, Jancik S, Slavkovsky R, Holinkova V, Rabcanova M, Vojta P, et al.
Electrophoresis
. 2015 Feb;
36(6):937-40.
PMID: 25655305
Whole genome amplification replicates the entire DNA content of a sample and can thus help to circumvent material limitations when insufficient DNA is available for planned genetic analyses. However, there...
4.
Xu Y, Kanagaratham C, Jancik S, Radzioch D
Methods Mol Biol
. 2013 Feb;
977:79-93.
PMID: 23436355
Promoter deletion analysis is a useful tool for identifying important regulatory regions involved in transcriptional control of gene expression. In this approach, a series of promoter deletion fragments are fused...
5.
Jancik S, Drabek J, Berkovcova J, Xu Y, Stankova M, Klein J, et al.
J Exp Clin Cancer Res
. 2012 Sep;
31:79.
PMID: 22995035
Background: It is mandatory to confirm the absence of mutations in the KRAS gene before treating metastatic colorectal cancers with epidermal growth factor receptor inhibitors, and similar regulations are being...
6.
Jancik S, Drabek J, Radzioch D, Hajduch M
J Biomed Biotechnol
. 2010 Jul;
2010:150960.
PMID: 20617134
The KRAS gene (Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) is an oncogene that encodes a small GTPase transductor protein called KRAS. KRAS is involved in the regulation of cell...